FDA approves H. Lundbeck A/S and Otsuka Pharmaceutical Co Ltd’s anti-psychotic drug Rexulti for the treatment of schizophrenia. The approval follows the results of seven clinical trials, three of which examines its effects on schizophrenia and four of which examines its effects on major depressive disorder (MDD).
Do you love news? Help us add and summarize the world's news. Find out more